Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ESRRA | P11474 | 5/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200663 | 1.00 | MCHR1 (0.56) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL13751602 | 1.00 | MCHR1 (0.56) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL4166895 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL4156815 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL2200745 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL13751829 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL13751838 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL2201001 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL2199367 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB | |
| SCHEMBL2199239 | 0.96 | MCHR1 (0.54) | MCHR1MEN1KMT2AFOXM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197870-A1 | Pharmaceutical Compositions | EXELIXIS, INC. (US) | 2009-08-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197870-A1 | Pharmaceutical Compositions | ESRRA, ESRRB, ESR2 | MCHR1 523/4885MEN1 3649/4885KMT2A 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.